North & Central America

This archive covers progress stories from North and Central America, spanning the U.S., Canada, Mexico, and the nations of Central America. Readers will find reporting on health, environment, community resilience, and policy advances across the region.

Abstract visual, for article on LSD-based drug

Single dose of LSD-based drug shows significant depression relief in key Phase 3 trial

A single-dose LSD-based drug has just cleared one of medicine’s highest evidentiary bars — offering meaningful, durable relief from major depressive disorder in a rigorous Phase 3 trial. DT120 ODT, a pharmaceutically refined lysergide compound, produced an 8.1-point improvement on the standard depression scale compared to placebo, with nearly all side effects mild and resolving the same day. For the millions who cycle through daily antidepressants without real relief, a single-dose model represents a genuinely different kind of hope — and a signal that psychedelic-assisted medicine is maturing into a serious contender in mainstream psychiatric care.

EV charging stations at night, for article on public EV charging ports

U.S. now has 250,000 public EV charging ports, more than doubling since 2021

Public EV charging in America has doubled since 2021, and the milestone reveals just how fast the country’s clean transportation backbone is growing. The U.S. now has over 250,000 public charging ports — and thousands more are already in the pipeline. Fast chargers are spreading along major travel corridors, while libraries, restaurants, and retailers are quietly adding chargers that work while you live your life. Every country watching this buildout sees proof that large-scale EV infrastructure is achievable — and that momentum, once established, is hard to stop.

Person giving blood, for article on blood donation ban

Canada removes ban on blood donations from gay men

Canada’s shift to behaviour-based blood donation screening closes a 30-year chapter in which gay and bisexual men were turned away not because of anything they did, but because of who they are. Starting September 30, 2022, donors will be assessed on individual risk behaviours — the same standard applied to everyone else. More than eight countries, including the U.K., France, and Brazil, have already made similar moves, signalling a global reckoning with policies that lagged far behind the science. This is what it looks like when health systems finally catch up to both the evidence and human dignity.

School bus on the road, for article on electric school bus mandate

New York enacts first-in-nation plan to electrify all state school buses

New York’s commitment to electrifying all 50,000 of its school buses sets a new standard for what statewide climate and children’s health policy can look like together. More than two million students — disproportionately from low-income communities — currently ride to school in diesel buses linked to asthma, reduced lung development, and cognitive harm. At least $500 million in state funding, paired with federal support, gives districts a real financial path forward. For advocates working to make clean air a guarantee rather than a privilege, this is a proof of concept other states can follow.

Stethoscope on top of a stock of hundred dollar bills, for article on medical debt cancellation, for article on medical debt cancellation, for article on medical debt cancellation

Connecticut has erased $513 million in medical debt for 250,000 residents since 2024

Medical debt relief is reaching Connecticut residents automatically — no application, no paperwork, just a letter confirming the debt is gone. The state partnered with a nonprofit that purchases debt portfolios at steep discounts, meaning every $6.5 million in public funding has erased roughly $100 in debt for every dollar spent. Relief flows automatically to residents earning under 400% of the federal poverty level, or whose medical debt exceeds 5% of their annual income. Because medical debt falls hardest on people already facing barriers to care, this model — now spreading across multiple states — points toward something genuinely replicable.

Busy Chicago street, for article on U.S. homicide rate

U.S. homicides dropped 21% in 2025, to likely the lowest rate in 125 years

Homicides in the U.S. fell faster in 2025 than any single year on record, and researchers say the rate may now be the lowest since 1900 — a remarkable marker in a decades-long arc toward safer cities. The drop touched nearly every major crime category and 27 of 35 cities studied, from Richmond to Los Angeles. Experts point to community intervention programs, stronger social fabric rebuilt after pandemic disruption, and courts finally functioning again. It’s a reminder that safety improves when people, institutions, and neighborhoods work together — and that sustained, human-centered investment can move the needle in lasting ways.

plastic pellets, aka nurdles, on a beach, for article on plastic pellet pollution law

Illinois becomes first Great Lakes state to pass plastic pellet pollution law

In a watershed moment for tackling industrial pollution at its source, Illinois has become the first Great Lakes state to hold plastic pellet makers legally accountable for spills. These lentil-sized beads, called nurdles, escape during production and shipping, poison waterways, and get mistaken for food by fish and birds; an estimated 22 million pounds of plastic waste enters the Great Lakes yearly. The new law classifies nurdles as pollutants, requires spill-prevention plans from producers, and directs the state to develop stormwater controls — shifting cleanup costs off communities and onto industry across one of the world’s most critical freshwater systems.

New York City park, for article on urban forest plan

New York City’s first urban forest plan targets its hottest, least-shaded blocks

New York City’s first Urban Forest Plan aims to grow tree canopy from 23.4% to 30% of the city’s surface by 2040, with a focus on neighborhoods that have been left in the sun for too long. Right now, environmental justice communities sit under about 19% canopy cover, while wealthier areas enjoy 26% — a gap you can feel on a hot summer afternoon. The plan protects existing trees, expands planting on streets and private land, and trains residents, including NYCHA tenants, to care for the urban forest. It’s a hopeful reminder that shade, cooler air, and cleaner streets are infrastructure every neighborhood deserves.

Depiction of DNA, for article on gene therapy for inherited deafness

U.S. FDA approves first-ever gene therapy for inherited deafness, free to patients

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families.
In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within six months, and five regained normal hearing, including the ability to hear whispers. Instead of charging the millions per child that’s common for rare-disease therapies, Regeneron chose a different path. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag. Called Otarmeni, the one-time treatment uses two harmless viruses to deliver working copies of the OTOF gene deep into the inner ear, restoring otoferlin, the protein the cochlea needs to turn sound into signals the brain can read. Its maker, Regeneron, says it will offer the therapy free to patients in the U.S. Doctors who ran the trial described children responding to their parents’ voices, and to music, for the first time.
This particular genetic form of deafness is rare, affecting roughly 50 babies born in the U.S. each year. But researchers believe the breakthrough cracks open the door to gene therapies for many other inherited conditions worldwide.

Finger prick insulin injection, for article on once-weekly insulin

Once-weekly insulin wins U.S. approval, cutting 365 injections a year to 52

Once-weekly insulin just became reality in the U.S., dropping the routine for many adults with type 2 diabetes from 365 shots a year to about 52. The FDA approved Awiqli after four phase 3 trials, covering 2,680 adults, found it matched or outperformed daily basal insulin in lowering blood glucose. For people already taking a weekly GLP-1 medication, pairing the two could mean far fewer injection days and one less thing to remember. Doctors are urging thoughtful, individualized use, especially around hypoglycemia risk and affordability. Still, with more than 500 million adults living with diabetes worldwide, treatments that make daily life easier are a quietly powerful step forward for global health.